高级检索
    胡毅, 刘思阳. 非小细胞肺癌患者PD-1通路抑制剂客观缓解率低与EGFR突变或ALK阳性有关[J]. 循证医学, 2017, 17(1): 46-49. DOI: 10.12019/j.issn.1671-5144.2017.01.013
    引用本文: 胡毅, 刘思阳. 非小细胞肺癌患者PD-1通路抑制剂客观缓解率低与EGFR突变或ALK阳性有关[J]. 循证医学, 2017, 17(1): 46-49. DOI: 10.12019/j.issn.1671-5144.2017.01.013
    shu
    HU Yi, LIU Si-yang. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(1): 46-49. DOI: 10.12019/j.issn.1671-5144.2017.01.013
    Citation: HU Yi, LIU Si-yang. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(1): 46-49. DOI: 10.12019/j.issn.1671-5144.2017.01.013
    shu

    非小细胞肺癌患者PD-1通路抑制剂客观缓解率低与EGFR突变或ALK阳性有关

    EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer

      摘要
      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回